Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma

• Status: Completed
• Trial end date: 2006-09-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: National Cancer Institute (NCI)

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven relapsed or refractory neuroblastoma

• Measurable disease

PATIENT CHARACTERISTICS:

Age:

• Children

Performance status:

• ECOG 0-2

Life expectancy:

• At least 2 months

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 1.5 mg/dL

• SGOT and SGPT less than 2.5 times upper limit of normal (ULN)

• Adequate liver function unless due to disease

Renal:

• Creatinine no greater than 1.5 times ULN OR

• Creatinine clearance at least 60 mL/min

• Adequate renal function unless due to disease

Other:

• No other serious concurrent illness

• No active uncontrolled infection

• Not pregnant

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Recovered from prior immunotherapy

• Prior autologous bone marrow transplantation allowed

• No concurrent immunotherapy

Chemotherapy:

• At least 4 weeks since prior chemotherapy and recovered

• No other concurrent systemic chemotherapy

Endocrine therapy:

• Not specified

Radiotherapy:

• Recovered from prior radiotherapy

Surgery:

• Not specified